Oculis (NASDAQ:OCS) Price Target Cut to $40.00 by Analysts at Stifel Nicolaus

Oculis (NASDAQ:OCS) had its target price dropped by equities researchers at Stifel Nicolaus from $50.00 to $40.00 in a research report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ target price indicates a potential upside of 173.19% from the stock’s current price.

Several other analysts also recently weighed in on the company. HC Wainwright cut their target price on Oculis from $47.00 to $26.00 and set a “buy” rating on the stock in a research note on Monday. JPMorgan Chase & Co. lifted their target price on Oculis from $38.00 to $42.00 and gave the company an “overweight” rating in a research note on Monday, May 18th. Needham & Company LLC dropped their price objective on Oculis from $46.00 to $38.00 and set a “buy” rating on the stock in a research note on Monday. Guggenheim dropped their price objective on Oculis from $75.00 to $45.00 and set a “buy” rating on the stock in a research note on Monday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a research note on Tuesday, April 21st. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Oculis has a consensus rating of “Moderate Buy” and a consensus price target of $40.75.

Oculis Stock Performance

NASDAQ:OCS traded down $8.06 during midday trading on Monday, reaching $14.64. 4,054,351 shares of the company traded hands, compared to its average volume of 415,235. The company has a fifty day moving average price of $27.68 and a 200 day moving average price of $25.21. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.18 and a quick ratio of 5.18. The firm has a market capitalization of $848.94 million, a price-to-earnings ratio of -6.87 and a beta of 0.23. Oculis has a twelve month low of $14.16 and a twelve month high of $34.47.

Oculis (NASDAQ:OCS) last announced its earnings results on Friday, May 8th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.14). The business had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.25 million. Oculis had a negative net margin of 8,460.67% and a negative return on equity of 56.78%. On average, analysts expect that Oculis will post -2.21 EPS for the current fiscal year.

Institutional Trading of Oculis

Institutional investors have recently bought and sold shares of the company. Bank of America Corp DE lifted its holdings in Oculis by 2.2% during the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after buying an additional 878 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Oculis by 100.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock valued at $40,000 after purchasing an additional 1,000 shares during the last quarter. Aventura Private Wealth LLC acquired a new stake in Oculis in the 4th quarter valued at about $80,000. Geode Capital Management LLC lifted its stake in Oculis by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after purchasing an additional 6,384 shares during the last quarter. Finally, Koshinski Asset Management Inc. acquired a new stake in Oculis in the 1st quarter valued at about $238,000. Institutional investors and hedge funds own 22.30% of the company’s stock.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.